TRUTAKNA
(Atacicept)Phase 3Protein / enzyme
TRUTAKNA is a protein / enzyme that works as a Tumor Necrosis Factor Ligand Superfamily Member 13b Inhibitor; Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor.[2] It is being investigated across 4 indications, with its most advanced program in Phase 3.[1]
TRUTAKNA is one of 38 small molecule programs targeting IgA Nephropathy (IgAN). It is currently in Phase 3.
4
Indications
18
Total Trials
4
Active Trials
37
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RocheApproved
Lorelco
SanofiApproved
Fabhalta
NovartisApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Vanrafia
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus Nephritis3 trials
Rheumatoid Arthritis3 trials
Systemic Lupus Erythematosus2 trials
Multiple Sclerosis2 trials
6 more indications
Long-term Follow-up1 trial
pMN1 trial
IgA Nephropathy (IgAN)1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jul 7, 2026
TRUTAKNA
BLA BLA761486
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atacicept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tumor Necrosis Factor Ligand Superfamily Member 13b Inhibitor; Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor[2]
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- VVera Therapeutics, Inc.